Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease
Status:
Terminated
Trial end date:
2017-04-12
Target enrollment:
Participant gender:
Summary
This study will evaluate a new ophthalmic formulation of cyclosporine (Restasis® X) in
patients with moderate to severe dry eye disease in two stages. Up to 3 doses will be studied
in Stage 2 based on results from Stage 1. No patients participating in Stage 1 will
participate in Stage 2 of this study. This study was terminated and Stage 2 of the study was
cancelled.